Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe c ...
For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals Co-Chief Executive Officer, HOPE Therapeutics, Inc. [email protected] SOURCE NRx Pharmaceuticals, Inc.